Biogen (BIIB) on Watch Ahead of Amyloid Antibodies NCD Wed - Cowen
Tweet Send to a Friend
Cowen analyst Phil Nadeau reiterated an Outperform rating and $375.00 price target on Biogen (NASDAQ: BIIB) ahead of the amyloid ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
